跳至主要内容
临床试验/NL-OMON53305
NL-OMON53305招募中不适用

Assessing Frequency of HLA-Genotype and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for Novel T Cell Receptor Based Therapies - Assessing Frequency of HLA-Genotype for TCR Based Therapies

T-knife GmbH0 个研究点目标入组 400 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
T-knife GmbH
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Signed written informed consent.
  • 2. Histologically or cytologically confirmed diagnosis of relapsed/refractory,
  • advanced stage solid tumor that may express MAGE-A1.
  • 3. Subject received at least one line of approved systemic therapy and is
  • declared to be in a non-curable disease state as per treating physician*s
  • current assessment.
  • 4. Availability of a stored, accessible tumor sample for IHC.
  • 5. Ability to provide a blood sample.
  • 6. Age >= 18 years.
  • 7. Life expectancy > 6 months as per treating physician*s assessment.

排除标准

  • 1. Any bleeding or coagulation disorder or other condition that would present
  • the subject with an undue risk when undergoing a venous blood draw.
  • 2. Any other condition that could interfere with subject's safety, obtaining
  • informed consent, or compliance to the screening study procedures.
  • 3. Presence of any organ toxicities or other conditions that would preclude
  • intense future anticancer treatments such as required for T cell receptor

研究者

发起方
T-knife GmbH

相似试验